Stress Cardiac MRI Using Regadenoson for Evaluation of Nonspecific Allograft Dysfunction
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 14
- 试验地点
- 1
- 主要终点
- Myocardial Perfusion Reserve
研究概览
简要总结
The investigators will use cardiac MRI to measure the myocardial perfusion reserve and amount of myocardial edema and fibrosis in heart-transplant patients with nonspecific allograft dysfunction in contrast to those with normal graft function. The investigators hypothesize that patients with nonspecific allograft dysfunction will demonstrate decreased myocardial perfusion reserve, related to microvascular allograft vasculopathy, compared to those with normal graft function.
详细描述
Adult heart-transplant patients, excluding those with a GFR less than 30 mL/min/1.73m2, contraindications to MRI and allergies to either regadenoson or gadolinium contrast, will be enrolled over 10 months. Patients will be recruited from UC San Diego and San Diego Veterans Affairs. The investigators will specifically enroll patients with nonspecific allograft dysfunction and patients with normal graft function.
Brief protocol:
Cardiac MRI is performed. Cine images in standard views are obtained. T2 mapping sequences are performed on short axis images. For stress imaging, intravenous regadenoson is given as a 0.4 mg bolus followed by a 5 mL saline flush. After 30 seconds, short-axis images are acquired for 30 consecutive heartbeats with administration of gadolinium. Rest imaging is performed 30 minutes after stress imaging. Lastly, late gadolinium enhancement images are obtained in standard views. Images are analyzed offline by a blinded independent reader. Patients will be followed for one month after enrollment for MACE.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age greater than or equal to 18 years old.
- •At least three months status post heart transplantation.
- •Heart-transplant patients with normal graft function (left ventricular ejection fraction equal to or greater than 55%) and no prior history of clinically significant acute rejection episodes that required modification of the immunosuppressive regimen or cardiac allograft vasculopathy.
- •Heart-transplant patients with nonspecific allograft dysfunction (left ventricular ejection fraction equal to or less than 50% AND decrease from post-transplant baseline ejection fraction by an absolute difference of 10% or greater, no formal diagnosis of allograft vasculopathy by coronary angiogram or coronary vascular ultrasonography, and no history of prior acute rejection episodes known to have decreased left ventricular ejection fraction to or less than 50%).
排除标准
- •Biopsy proven acute rejection episode in the past 3 months.
- •Patients with symptoms or signs of acute myocardial ischemia or recent acute coronary syndrome in the past 3 months.
- •Uncontrolled obstructive ventilatory disease including asthma and COPD.
- •Second or third degree AV nodal block.
- •Sinus node dysfunction.
- •Contraindications to MRI including pacemakers or implantable cardioverter-defibrillators.
- •Renal dysfunction with an estimated GFR less than 30 mL/min/1.73m
- •Prior adverse reaction to either regadenoson or gadolinium contrast. Prior adverse reaction to adenosine will be assessed on a case-by-case basis.
- •Any invasive procedure, including endomyocardial biopsy and left coronary angiogram, performed within one week.
- •Systolic blood pressure greater than 180 or less than 85 mmHg.
- •Diastolic blood pressure greater than 120 or less than 40 mmHg.
- •Resting heart rate greater than 120 or less than 45 beats per minute.
- •Severe claustrophobia.
研究组 & 干预措施
Nonspecific allograft dysfunction
Patients with nonspecific allograft dysfunction will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart.
干预措施: Regadenoson (Drug)
Nonspecific allograft dysfunction
Patients with nonspecific allograft dysfunction will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart.
干预措施: Gadolinium (Drug)
Nonspecific allograft dysfunction
Patients with nonspecific allograft dysfunction will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart.
干预措施: Cardiac MRI (Procedure)
Normal graft function
Patients with normal graft function will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart.
干预措施: Regadenoson (Drug)
Normal graft function
Patients with normal graft function will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart.
干预措施: Gadolinium (Drug)
Normal graft function
Patients with normal graft function will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart.
干预措施: Cardiac MRI (Procedure)
结局指标
主要结局
Myocardial Perfusion Reserve
时间窗: Range of 1 to 12 years after heart transplantation for subjects and an average of 4 years after heart-transplantation.
Myocardial perfusion reserve calculates the increase in myocardial perfusion after stress in comparison to rest. Outcome measure time frame specifies when the myocardial perfusion reserve was obtained in relation to date of heart-transplant for each patient. This was a one time measurement made after heart-transplantation.
次要结局
- Hospitalization for Cardiac Related Causes(10 months after enrollment (from date of cardiac MRI))
- Re-transplantation(10 months after enrollment (from date of cardiac MRI))
- Mean Segmental T1 Values of the Left Ventricle(Range of 1 to 12 years after heart transplantation for subjects and an average of 4 years after heart-transplantation.)
- Late Gadolinium Enhancement(Range of 1 to 12 years after heart transplantation for subjects and an average of 4 years after heart-transplantation.)
- Myocardial Ischemia/Infarction(10 months after enrollment (when cardiac MRI was performed))
研究者
Paul Kim
Cardiology Fellow
Stanford University